Daily Cardiology Research Analysis
Three high-impact cardiology studies advance practice across revascularization, device strategy, and risk stratification. An economic analysis from the FAME 3 randomized trial shows FFR-guided PCI delivers comparable quality-adjusted survival to CABG at substantially lower 5-year costs. The REC-CAGEFREE I randomized trial reports higher 3-year device-oriented events with a drug-coated balloon strategy versus upfront DES, while a nationwide JACC registry demonstrates the Clinical Frailty Scale in
Summary
Three high-impact cardiology studies advance practice across revascularization, device strategy, and risk stratification. An economic analysis from the FAME 3 randomized trial shows FFR-guided PCI delivers comparable quality-adjusted survival to CABG at substantially lower 5-year costs. The REC-CAGEFREE I randomized trial reports higher 3-year device-oriented events with a drug-coated balloon strategy versus upfront DES, while a nationwide JACC registry demonstrates the Clinical Frailty Scale independently predicts 2-year mortality in heart failure and improves prognostic discrimination.
Research Themes
- Cost-effectiveness of PCI versus CABG in multivessel CAD
- Device strategy for de novo coronary lesions: DCB versus DES
- Frailty-based prognostication in heart failure
Selected Articles
1. Economic Outcomes and Quality of Life After CABG or PCI for Multivessel Disease: The FAME 3 Trial.
In the FAME 3 randomized trial of 1,500 patients with 3-vessel CAD, FFR-guided PCI using zotarolimus-eluting stents achieved similar 5-year QALYs to CABG at substantially lower cumulative costs. PCI yielded faster early quality-of-life gains and higher 5-year employment in patients <65, and offered superior economic value in most bootstrap replications.
Impact: This head-to-head randomized comparison provides contemporary, long-horizon economic and QOL evidence directly informing revascularization strategy selection in multivessel CAD. It challenges the assumption of default CABG cost-effectiveness by demonstrating superior value of FFR-guided PCI.
Clinical Implications: For eligible multivessel CAD patients, FFR-guided PCI can deliver comparable patient-centered outcomes at lower 5-year costs than CABG, supporting PCI as a high-value option when anatomy and clinical factors permit. Shared decision-making should incorporate economic and recovery considerations alongside clinical outcomes.
Key Findings
- Five-year cumulative costs were 30% higher with CABG; QALYs were similar between PCI (4.05) and CABG (4.03).
- Early EQ-5D improvement was faster after PCI; among patients <65 years, employment at 5 years favored PCI (56% vs 47%).
- Bootstrapping showed PCI had lower costs and higher QALYs in 66% of replications; CABG’s ICER exceeded $150,000/QALY in 98%.
Methodological Strengths
- Randomized, multicenter design with 5-year follow-up and prespecified economic endpoints
- Use of standardized EQ-5D utilities and rigorous cost modeling with extensive bootstrap uncertainty analysis
Limitations
- Open-label design; costs based on Medicare reimbursement may limit generalizability across health systems
- Device and strategy reflect zotarolimus DES with FFR guidance; results may not generalize to all stent types or non-FFR strategies
Future Directions: Assess cost-effectiveness across diverse payers and countries, evaluate alternative DES/polymers and physiology-guided strategies, and extend lifetime modeling with real-world data.
BACKGROUND: Previous studies have found coronary artery bypass grafting (CABG) to be cost-effective compared with percutaneous coronary intervention (PCI) among patients with multivessel coronary artery disease (CAD), but their comparative effectiveness and economic outcomes may have changed. OBJECTIVES: This study sought to compare the economic and quality of life outcomes of CABG vs PCI and determine their cost-effectiveness in the FAME (Fractional Flow Reserve vs Angiography for Multivessel Evaluation) 3 randomized trial. METHODS: FAME 3 randomly assigned 1,500 patients with 3-vessel CAD to either CABG or fractional flow reserve-guided PCI using zotarolimus drug-eluting stents. We documented resource use and quality of life over 5 years of follow-up. We calculated costs by applying Medicare reimbursement rates to resources used, assessed quality of life using the EuroQOL EQ-5D, calculated quality-adjusted life-years (QALYs) from EQ-5D utility values, and used multivariable regression to compare outcomes by treatment assignment. We calculated the incremental cost-effectiveness ratio based on 5-year outcomes and also on projected life expectancies, and assessed its variability in 10,000 bootstrap replications. RESULTS: Cumulative costs over 5 years were 30% higher in patients assigned to CABG (95% CI: 16%-46%; P < 0.001). QALYs over 5 years did not differ significantly between the PCI (4.05 ± 0.84) and CABG groups (4.03 ± 0.82), although EQ-5D scores improved more rapidly after PCI. Patients <65 years of age at enrollment assigned to PCI were more likely to be employed at 5 years (56% vs 47%; P = 0.025). PCI had greater economic value than CABG over 5 years, with lower costs and higher QALYs in 66% of replications, and incremental cost-effectiveness ratios for CABG above the $150,000/QALY benchmark in 98% of bootstrap replications. These findings were essentially unchanged in several lifetime projections based on the outcomes documented within the trial follow-up period. CONCLUSIONS: Fractional flow reserve-guided PCI using zotarolimus drug-eluting stents provides significantly better long-term value than CABG for treatment of patients with multivessel CAD, with equivalent clinical outcomes at substantially lower cost.
2. Drug-Coated Balloon Angioplasty vs Up-Front Stenting for De Novo CAD: 3-Year Follow-Up of REC-CAGEFREE I Trial.
In 2,272 patients with de novo CAD randomized to DCB with provisional stenting vs upfront DES, the 3-year device-oriented composite endpoint was higher with the DCB strategy (8.2% vs 5.0%). Landmark analyses suggest the excess accrued early and persisted, challenging generalized use of a DCB-first approach for de novo lesions.
Impact: This large randomized comparison directly informs device selection for de novo lesions, showing clinically relevant inferiority of a DCB-first strategy over modern thin-strut DES at mid-term follow-up.
Clinical Implications: For de novo CAD, upfront implantation of second-generation sirolimus-eluting stents remains the preferred strategy given lower 3-year device-oriented events. DCB use may be best reserved for specific scenarios (e.g., ISR, small vessels) pending further evidence.
Key Findings
- At 3 years, DOCE was higher with DCB strategy vs DES (8.2% vs 5.0%; absolute difference 3.21%; P=0.002).
- Provisional rescue DES was required in 9.4% of DCB-assigned patients, indicating frequent need for crossover.
- Landmark analyses indicated most of the difference accrued in the first year, with persistence through year 3.
Methodological Strengths
- Large, multicenter randomized design with 3-year follow-up and intention-to-treat analysis
- Broad inclusion across vessel diameters with standardized device strategies
Limitations
- Open-label design; trial conducted in China may limit generalizability to other populations
- Use of paclitaxel-coated balloons versus sirolimus DES may confound class comparisons
Future Directions: Define patient subsets where DCB provides equivalent outcomes (e.g., small vessels) and test newer-generation DCBs against contemporary DES in global populations with longer follow-up.
BACKGROUND: Owing to the absence of a metallic scaffold, percutaneous coronary intervention (PCI) with drug-coated balloons (DCBs) may cause less chronic inflammation and potentially reduce late complications compared with drug-eluting stents (DES). However, in the REC-CAGEFREE I study, the strategy of DCB angioplasty with rescue stenting failed to achieve noninferiority to intended DES implantation for treating de novo lesions at 2 years. OBJECTIVE: This study sought to investigate the 3-year outcomes of the REC-CAGEFREE I trial and assess the mid-term effects of DCBs compared with DES. METHODS: REC-CAGEFREE I was an open-label, randomized, noninferiority trial conducted across 43 sites in China. After successful lesion predilation, 2,272 patients with de novo coronary artery disease (regardless of target vessel diameter) were randomly assigned (1:1) to paclitaxel-coated balloon angioplasty with the option of rescue stenting (DCB arm) vs up-front deployment of second-generation thin-strut sirolimus-eluting stents (DES arm). The primary outcome was the device-oriented composite endpoint (DOCE; including cardiovascular death, target vessel myocardial infarction [TV-MI], and clinically and physiologically indicated target lesion revascularization [CPI-TLR]) assessed in the intention-to-treat population. The extended follow-up is ongoing and will continue for up to 10 years. RESULTS: From February 5, 2021, to May 1, 2022, 1,133 patients were randomly assigned to the DCB arm and 1,139 to the DES arm. The median diameter of devices was at 3.00 ± 0.46 mm. Rescue DES implantation after unsatisfactory DCB angioplasty was performed in 106 patients (9.4%). At 3 years, the DOCE occurred in 92 patients (8.2%) in the DCB arm and 56 (5.0%) in the DES arm (difference: 3.21%; 95% CI: 1.17%-5.26%; P = 0.002). Landmark analyses showed that the rates of difference in the DOCE at 0 to 1, 1 to 2, and 2 to 3 years were 1.69% (95% CI: 0.32%-3.06%), 1.10% (95% CI: -0.13% to 2.32%), and 0.58% (95% CI: -0.51% to 1.66%), respectively (P CONCLUSIONS: In patients with de novo coronary artery disease, DCB angioplasty with rescue stenting was associated with a higher rate of the DOCE compared with up-front DES implantation regarding the DOCE at 3 years. (Paclitaxel-Coated Balloon for Treatment of De-Novo Noncomplex Coronary Artery Lesions; NCT04561739).
3. Frailty Scale Captures Multidimensional Vulnerability and Predicts Mortality in Heart Failure.
In 3,905 hospitalized HF patients from a nationwide prospective registry, higher CFS categories were associated with progressively worse physical and cognitive performance and stepwise increases in 2-year all-cause mortality. Incorporating CFS into prognostic models improved discrimination over models using SPPB and Mini-Cog alone.
Impact: The study validates a simple, clinically intuitive frailty scale as an independent, integrative predictor of mortality in HF, supporting its routine use to enhance risk stratification beyond performance tests.
Clinical Implications: Integrate CFS into discharge planning and ambulatory HF care to identify high-risk patients for tailored interventions (e.g., multidisciplinary rehab, nutrition, cognitive support) and to refine shared decision-making.
Key Findings
- CFS severity correlated with worse gait speed, chair-stand, SPPB, grip strength, 6MWD, and Mini-Cog scores.
- Two-year all-cause mortality was 18.6% overall and increased stepwise with higher CFS categories.
- Adding CFS to prognostic models significantly improved discrimination beyond SPPB and Mini-Cog.
Methodological Strengths
- Prospective nationwide multicenter registry with large sample size
- Comprehensive assessment across physical and cognitive domains with standardized tools
Limitations
- Observational design with potential residual confounding
- CFS assessment may be subject to interrater variability; generalizability primarily to hospitalized HF population
Future Directions: Test CFS-guided intervention pathways to reduce mortality and rehospitalization; evaluate integration with biomarkers and imaging for multidimensional risk staging.
BACKGROUND: Frailty is prevalent in patients with heart failure and is associated with adverse outcomes. However, the extent to which the Clinical Frailty Scale (CFS) accurately captures physical and cognitive decline and its prognostic utility in contemporary heart failure care remain uncertain. OBJECTIVES: In this study, the authors sought to examine how well the CFS reflects domains of physical and cognitive function and its association with 2-year all-cause mortality in hospitalized patients with heart failure, using data from the Japanese Registry of Acute Decompensated Heart Failure-Next (JROADHF-NEXT). METHODS: This study involved 3,905 patients from a prospective, nationwide, multicenter registry focusing on hospitalized patients with heart failure (JROADHF-NEXT). Patients were stratified into 6 categories (1-2, 3, 4, 5, 6, and 7-9) according to the CFS. Physical function was assessed using gait speed, the 5-chair stand test, the Short Physical Performance Battery (SPPB), grip strength, and 6-minute walk distance; cognitive function was measured using the Mini-Cog test. The primary outcome was 2-year all-cause mortality after discharge. RESULTS: Physical function metrics and Mini-Cog scores progressively worsened with increasing CFS severity. Over a 2-year follow-up, 725 patients (18.6%) died, with mortality increasing stepwise with higher CFS scores. Adding CFS to the prognostic model significantly improved discrimination compared with a model based on the SPPB and Mini-Cog test. CONCLUSIONS: The CFS is an independent predictor of 2-year mortality and a robust integrative measure of physical and cognitive vulnerability in patients with heart failure. The CFS provides a practical screening tool that complements formal performance-based frailty assessments in contemporary heart failure management.